Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + Lenvatinib + GEMOX Conversion Therapy in Locally Advanced Cholangiocarcinoma
ChiCTR2600120552Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, lenvatinib, gemcitabine and oxaliplatin in biliary cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC) and 1 more, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: R0 resection rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinibgemcitabineoxaliplatin
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600120552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120552.